Alnylam Pharma (ALNY) Tops Q3 EPS by 15c, Misses on Revenue, Offers FY22 Revenue Guidance

Alnylam Pharma (NASDAQ: ALNY) reported Q3 EPS of ($1.58), $0.15 better than the analyst estimate of ($1.73). Revenue for the quarter came in at $264.3 million versus the consensus estimate of $293.08 million.

GUIDANCE:

Alnylam Pharma sees FY2022 revenue of $870-930 million, versus the consensus of $1.02 Billion.

For earnings history and earnings-related data on Alnylam Pharma (ALNY) click here.

You May Also Be Interested In

• Freightos Limited (CRGO) Tops Q2 EPS by 3c ; Offers Guidance
• L3Harris CEO steps down amid conduct review, shares drop
• Jasper Therapeutics (JSPR) Tops Q2 EPS by 18c